Neuromotus: A novel neuroplastic treatment for Phantom Limb Pain
|Coordinator||CHALMERS TEKNISKA HÖGSKOLA AKTIEBOLAG - Institutionen för signaler och system|
|Funding from Vinnova||SEK 1 620 000|
|Project duration||September 2016 - August 2018|
Purpose and goal
This project enabled the clinical validation of a novel technology for the treatment of PLP, namely Neuromotus. Neuromotus overcomes technological limitations of current treatments while it remains non-invasive, low-risk, and apt for bilateral amputations. Moreover, Neuromotus offers a more engaging and effective therapy than currently available options. In this project, Neuromotus became a fully integrated device approved to be independently operated by the end user (clinicians and patients). The CE marking of Neuromotus was initiated and expected in early 2019.
Expected results and effects
PLP is a deteriorating condition for which there is currently no effective treatment; it tends to become chronic; and, it reduces the quality of life of patients and closer relatives. A successful treatment would not only provide relief and restore quality of life, but would also facilitate the reintegration of patients as productive members of society, which in turn would reduce the costs associated with the disability. The results of this project showed that Neuromotus is effective in reducing PLP and can be used by clinicians and patients independently from engineering staff.
Planned approach and implementation
This project was a truly multidisciplinary endeavor. It was coordinated by Chalmers University of Technology and conducted in close collaboration with three major hospitals in Sweden (Stockholm, Örebro, and Gothenburg) and one industrial partner (Integrum AB). An approved, safe, robust, and user-friendly device was developed by the consortium and used successfully in clinical environments and by patients at home.